# FDA Inspection 1182007 - UPMC Hillman Cancer Center Riviera Facility - October 18, 2022

Source: https://www.keypedia.com/records/fda_inspections/upmc-hillman-cancer-center-riviera-facility/b0364785-9daa-413d-933e-af1105c894e5
Source feed: FDA_Inspections

> FDA Inspection 1182007 for UPMC Hillman Cancer Center Riviera Facility on October 18, 2022. Classification: No Action Indicated (NAI).

---

## Details

- Record Type: FDA Inspection
- Inspection ID: 1182007
- Company Name: UPMC Hillman Cancer Center Riviera Facility
- Inspection Date: 2022-10-18
- Classification: No Action Indicated (NAI)
- Project Area: Human Cellular, Tissue, and Gene Therapies
- Product Type: Biologics
- Office Name: Center for Biologics Evaluation and Research

## Related Documents

- [FDA Inspection 1182007 - 2022-10-18](https://www.keypedia.com/records/fda_inspections/upmc-hillman-cancer-center-riviera-facility/63832308-b6ff-4284-bdf8-473f1b4adf55)
- [FDA Inspection 1182007 - 2022-10-18](https://www.keypedia.com/records/fda_inspections/upmc-hillman-cancer-center-riviera-facility/819be3bb-dae1-42eb-811f-24227f0201e3)

Company: https://www.keypedia.com/companies/upmc-hillman-cancer-center-riviera-facility/84ddbe15-26ba-4ae9-9e0d-c3e581e61ced

Office: https://www.keypedia.com/offices/center-for-biologics-evaluation-and-research/dd9e8ea7-6f04-4ed1-b0d7-e7e6b264570d